Newly reported from ACC 2024: Olezarsen Shows Ability to Reduce Triglycerides for Patients with FCS in BALANCE Trial
A phase 3 trial of olezarsen suggests the APOC3 inhibitor could prove useful in the management of familial chylomicronemia syndrome (FCS).
Results of the trial, called the BALANCE study, the olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides in patients with genetically validated FCS at 6 months, with further analysis demonstrating use was associated with a reduced incidence of acute pancreatitis events over 12 months relative to placebo.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
